Tourmaline Bio Inc. is a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases. The company's lead program includes TOUR006. Tourmaline Bio Inc., formerly known as Talaris Therapeutics Inc., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-73.21M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -26.75% |
| Return on Assets (Trailing 12 Months) | -26.11% |
| Current Ratio (Most Recent Fiscal Quarter) | 33.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 33.87 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.71 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.89 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.89 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 25.68M |
| Free Float | 22.86M |
| Market Capitalization | $473.64M |
| Average Volume (Last 20 Days) | 0.33M |
| Beta (Past 60 Months) | 2.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.02% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |